We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+6.71%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$118M
Cap. Flow
+$165M
Cap. Flow %
15.37%
Top 10 Hldgs %
83.78%
Holding
22
New
7
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ANNX icon
Annexon
ANNX
+$76.1M
2
NRIX icon
Nurix Therapeutics
NRIX
+$32.4M
3
KYMR icon
Kymera Therapeutics
KYMR
+$22.3M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$13.6M
5
NAUT icon
Nautilus Biotechnolgy
NAUT
+$10.7M

Top Sells

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$916K

Sector Composition

Rank Sector Weight
1 Healthcare 90.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$347M 32.35%
7,281,307
– –
ARQT icon
2
Arcutis Biotherapeutics
ARQT
$3.26B
$117M 10.87%
3,979,292
– –
ANNX icon
3
Annexon
ANNX
$883M
$98M 9.13%
+3,241,628
New +$76.1M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$73.4M 6.84%
4,080,237
– –
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
$64.2M 5.98%
137,827
– –
REPL icon
6
Replimune Group
REPL
$1.15B
$48.9M 4.55%
2,122,415
-40,183
-2% -$916K
DVAX
7
DELISTED
Dynavax Technologies
DVAX
$47.1M 4.39%
10,895,773
– –
NRIX icon
8
Nurix Therapeutics
NRIX
$2.69B
$44.8M 4.18%
+1,284,314
New +$32.4M
SAGE
9
DELISTED
Sage Therapeutics
SAGE
$30.5M 2.84%
499,100
– –
CNST
10
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$28.4M 2.64%
1,400,000
– –
KYMR icon
11
Kymera Therapeutics
KYMR
$9.03B
$23.6M 2.2%
+729,606
New +$22.3M
SVRA icon
12
Savara
SVRA
$1.17B
$23M 2.14%
5,128,593
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$9.29B
$19.1M 1.78%
108,000
– –
APTX
14
DELISTED
Aptinyx Inc. Common Stock
APTX
$18.8M 1.75%
5,558,425
– –
MRNS
15
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$18.4M 1.71%
1,431,059
– –
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$8.93B
$16.8M 1.56%
1,071,428
– –
PNT
17
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$14.4M 1.34%
+1,000,000
New +$13.6M
XFOR icon
18
X4 Pharmaceuticals
XFOR
$421M
$11.2M 1.04%
54,950
– –
NAUT icon
19
Nautilus Biotechnolgy
NAUT
$110M
$10.8M 1.01%
+1,000,000
New +$10.7M
SLDB icon
20
Solid Biosciences
SLDB
$918M
$7.86M 0.73%
258,078
– –
TNGX icon
21
Tango Therapeutics
TNGX
$4.51B
$5.18M 0.48%
+500,000
New +$5.11M
PANA.U
22
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$5M 0.47%
+500,000
New +$5.75M

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2020 Portfolio in Review

As of Q3 2020, Bain Capital Life Sciences Investors held 22 positions worth $1.07B, up 12% from $955M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Bain Capital Life Sciences Investors deployed $165M of net new capital in Q3 2020, opening 7 new positions. Its largest new stake was Annexon: 3,241,628 shares worth $98M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier.

On the sell side, the largest reduction was Replimune Group, an estimated $916K trimmed.

  • Bain Capital Life Sciences Investors's largest Q3 2020 buy was Annexon: 3,241,628 shares worth $98M.
  • Bain Capital Life Sciences Investors's biggest Q3 2020 reduction was Replimune Group, cutting an estimated $916K.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 84% of its $1.07B portfolio in Q3 2020.
  • Bain Capital Life Sciences Investors opened 7 new positions and closed 0 in Q3 2020.
  • Bain Capital Life Sciences Investors's portfolio value rose 12% quarter-over-quarter to $1.07B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2020, filed 16 Nov 2020.